Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Nivolumab and Nivolumab Combined With Ipilimumab in Patients With Melanoma Brain Metastases

NCT02374242 is registered in ClinicalTrials.gov with Melanoma Institute Australia as lead sponsor.

NCT NCT02374242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02374242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Nivolumab and Nivolumab Combined With Ipilimumab in Patients With Melanoma Brain Metastases
Lead sponsor
Melanoma Institute Australia
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 4, 2014
Completion date
December 31, 2028
Enrollment
76 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, melanoma